Central Pharmaceutical JSC No2 (HSTC:DP2) YoY EBITDA Growth: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DP2 Central Pharmaceutical JSC No2 HSTC:DP2
23 GF Score
Price ₫4,900.00
View Full Analysis

What is Central Pharmaceutical JSC No2 YoY EBITDA Growth?

Central Pharmaceutical JSC No2 HSTC:DP2 23 YoY EBITDA Growth is 0.00% as of . 20. GuruFocus rates HSTC:DP2 with a GF Score™ of 23/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Central Pharmaceutical JSC No2's YoY EBITDA Growth for the quarter that ended in . 20 was 0.00%.

Central Pharmaceutical JSC No2's EBITDA per Share for the six months ended in . 20 was ₫0.00.

Central Pharmaceutical JSC No2 YoY EBITDA Growth Related Terms

Central Pharmaceutical JSC No2 YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Central Pharmaceutical JSC No2's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceutical JSC No2 YoY EBITDA Growth Chart

Central Pharmaceutical JSC No2 Annual Data
Trend
YoY EBITDA Growth

Central Pharmaceutical JSC No2 Semi-Annual Data
YoY EBITDA Growth
HSTC:DP2
23GF Score
Central Pharmaceutical JSC No2 HSTC:DP2
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceutical JSC No2 YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Central Pharmaceutical JSC No2's YoY EBITDA Growth for the fiscal year that ended in . 20 is calculated as:

YoY EBITDA Growth (A: . 20 )
=(EBITDA per Share (A: . 20 )-EBITDA per Share (A: . 20 ))/ | EBITDA per Share (A: . 20 ) |
=(-)/ | |
=N/A %

Central Pharmaceutical JSC No2's YoY EBITDA Growth for the quarter that ended in . 20 is calculated as:

YoY EBITDA Growth (Q: . 20 )
=(EBITDA per Share (Q: . 20 )-EBITDA per Share (Q: . 20 )) / | EBITDA per Share (Q: . 20 ) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a YoY EBITDA Growth of 0.00% as of . 20. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Central Pharmaceutical JSC No2 and its competitors.
Is Central Pharmaceutical JSC No2's YoY EBITDA Growth too high?
Central Pharmaceutical JSC No2's current YoY EBITDA Growth is 0.00%. Overall, Central Pharmaceutical JSC No2 has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceutical JSC No2's YoY EBITDA Growth compare to ?
Central Pharmaceutical JSC No2's YoY EBITDA Growth of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Central Pharmaceutical JSC No2 and its competitors. Central Pharmaceutical JSC No2's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceutical JSC No2 stock overvalued right now?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Central Pharmaceutical JSC No2's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Central Pharmaceutical JSC No2 (HSTC:DP2), the current YoY EBITDA Growth is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Pharmaceutical JSC No2 Business Description

Comparable Companies
Address No. 9 Tran Thanh Tong, Bach Dang Ward, Hai Ba Trung District, Hanoi, VNM
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.
23GF Score

Get the complete analysis for HSTC:DP2

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫4,900.00
Price